The Impact of Pharmaceutical Care on Infection Control Measures Among Hemodialysis Patients. A Randomized Interventional Study.

IF 2.3 Q2 UROLOGY & NEPHROLOGY

International Journal of Nephrology and Renovascular Disease Pub Date : 2026-03-13 eCollection Date: 2026-01-01 DOI:10.2147/IJNRD.S585790

Raghad Saad Hussien, Kawa Ahmad Obeid

{"title":"The Impact of Pharmaceutical Care on Infection Control Measures Among Hemodialysis Patients. A Randomized Interventional Study.","authors":"Raghad Saad Hussien, Kawa Ahmad Obeid","doi":"10.2147/IJNRD.S585790","DOIUrl":null,"url":null,"abstract":"Purpose: This study seeks to highlight the impact of clinical pharmacists in protecting hemodialysis patients from catheter-related infections. By ensuring appropriate antimicrobial use, guiding patients on prevention practices, and collaborating with the healthcare team. This study also examines how pharmacists improve safety, treatment adherence, and quality of life.Patients and methods: This randomized interventional study was conducted between November 2024-April 2025. Patients were divided into intervention and non-intervention groups. The care bundle comprised culture-guided antibiotic locks (except gentamicin-heparin), in-hospital exit-site dressing with 3M Tegaderm by trained staff, and safety medication checks (e.g, blood-pressure monitoring before the use of erythropoiesis-stimulating agents) were used. The primary endpoint was the incidence of catheter-related bloodstream infections (CRBSIs); secondary endpoints were length of stay, admissions, ICU admissions, catheter replacements, and death. Monthly averages of vitals, drug therapy problems (DTPs), and laboratory parameters were obtained for both groups.Results: A total of ninety patients included in this study. The patients were randomly assigned to either the intervention or non-intervention group and a total 81 out of 90 patients successfully completed the study. After four visits and six months of implementing infection control measures within the context of pharmaceutical care, the infection rate showed a significant reduction in the intervention group (from 0.64±0.48 to 0.20±0.4, p =0.0001) compared with the non-intervention group (0.66±0.48 to 0.71±0.45, p =0.9731). The mean differences increased over time, reaching 0.26 (95% CI of diff.= 0.09 to 0.43) at visit 1, 0.41 (95% CI of diff.= 0.24 to 0.58) at visit 3, and 0.51 (95% CI of diff.= 0.34 to 0.68) at visit 4.Conclusion: Clinical pharmacist intervention via implementing infection control within the context of a pharmaceutical-care process can improve infection rates among hemodialysis patients.","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"19 ","pages":"585790"},"PeriodicalIF":2.3000,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12999364/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Nephrology and Renovascular Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/IJNRD.S585790","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study seeks to highlight the impact of clinical pharmacists in protecting hemodialysis patients from catheter-related infections. By ensuring appropriate antimicrobial use, guiding patients on prevention practices, and collaborating with the healthcare team. This study also examines how pharmacists improve safety, treatment adherence, and quality of life.

Patients and methods: This randomized interventional study was conducted between November 2024-April 2025. Patients were divided into intervention and non-intervention groups. The care bundle comprised culture-guided antibiotic locks (except gentamicin-heparin), in-hospital exit-site dressing with 3M Tegaderm by trained staff, and safety medication checks (e.g, blood-pressure monitoring before the use of erythropoiesis-stimulating agents) were used. The primary endpoint was the incidence of catheter-related bloodstream infections (CRBSIs); secondary endpoints were length of stay, admissions, ICU admissions, catheter replacements, and death. Monthly averages of vitals, drug therapy problems (DTPs), and laboratory parameters were obtained for both groups.

Results: A total of ninety patients included in this study. The patients were randomly assigned to either the intervention or non-intervention group and a total 81 out of 90 patients successfully completed the study. After four visits and six months of implementing infection control measures within the context of pharmaceutical care, the infection rate showed a significant reduction in the intervention group (from 0.64±0.48 to 0.20±0.4, p =0.0001) compared with the non-intervention group (0.66±0.48 to 0.71±0.45, p =0.9731). The mean differences increased over time, reaching 0.26 (95% CI of diff.= 0.09 to 0.43) at visit 1, 0.41 (95% CI of diff.= 0.24 to 0.58) at visit 3, and 0.51 (95% CI of diff.= 0.34 to 0.68) at visit 4.

Conclusion: Clinical pharmacist intervention via implementing infection control within the context of a pharmaceutical-care process can improve infection rates among hemodialysis patients.

Abstract Image

查看原文本刊更多论文

药学服务对血液透析患者感染控制措施的影响。一项随机介入研究。

目的：本研究旨在强调临床药师在保护血液透析患者免受导管相关感染方面的作用。通过确保适当使用抗菌素，指导患者采取预防措施，并与医疗保健团队合作。本研究还探讨了药剂师如何提高安全性、治疗依从性和生活质量。患者和方法：这项随机介入研究于2024年11月至2025年4月进行。将患者分为干预组和非干预组。护理包包括培养引导的抗生素锁（庆大霉素-肝素除外），由训练有素的工作人员在医院出口用3M Tegaderm敷药，以及安全药物检查（例如，使用促红细胞生成剂前的血压监测）。主要终点是导管相关血流感染（crbsi）的发生率；次要终点为住院时间、入院、ICU入院、导管更换和死亡。获得两组的月平均生命体征、药物治疗问题（dtp）和实验室参数。结果：本研究共纳入90例患者。患者被随机分配到干预组和非干预组，90名患者中有81名成功完成了研究。经过4次就诊和6个月的药学服务感染控制措施实施后，干预组的感染率（从0.64±0.48降至0.20±0.4,p =0.0001）明显低于非干预组（0.66±0.48降至0.71±0.45,p =0.9731）。随着时间的推移，平均差异增加，在第一次访问时达到0.26 (95% CI = 0.09 ~ 0.43)，在第3次访问时达到0.41 (95% CI = 0.24 ~ 0.58)，在第4次访问时达到0.51 （95% CI = 0.34 ~ 0.68）。结论：临床药师通过在药学服务过程中实施感染控制进行干预，可提高血液透析患者的感染率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Nephrology and Renovascular Disease UROLOGY & NEPHROLOGY-

CiteScore

3.90

自引率

5.00%

发文量

审稿时长

16 weeks

期刊介绍： International Journal of Nephrology and Renovascular Disease is an international, peer-reviewed, open-access journal focusing on the pathophysiology of the kidney and vascular supply. Epidemiology, screening, diagnosis, and treatment interventions are covered as well as basic science, biochemical and immunological studies. In particular, emphasis will be given to: -Chronic kidney disease- Complications of renovascular disease- Imaging techniques- Renal hypertension- Renal cancer- Treatment including pharmacological and transplantation- Dialysis and treatment of complications of dialysis and renal disease- Quality of Life- Patient satisfaction and preference- Health economic evaluations. The journal welcomes submitted papers covering original research, basic science, clinical studies, reviews & evaluations, guidelines, expert opinion and commentary, case reports and extended reports. The main focus of the journal will be to publish research and clinical results in humans but preclinical, animal and in vitro studies will be published where they shed light on disease processes and potential new therapies and interventions.